`LINGUAL
`
`CROSSLINGUAL, LLC
`3736 Fallon Road, Suite 226
`Dublin, CA 94568
`Tel: 206-851-7932
`
`hr@clingua|.com
`
`AFFIDAVIT OF TRANSLATION
`
`I, Alan F. Siegrist, of CROSSLINGUAL, LLC, hereby declare that:
`1.
`I am fluent in Japanese and English.
`2.
`I am an active member of the American Translators Association and a Certified
`
`Translator of Japanese to English.
`
`. The English translation attached to this declaration is an accurate and correct
`translation of the following document, attached hereto:
`
`2000.5 - 1st Edition [Bronuck Package Insert]
`I declare that the foregoing is true and correct to the best of my knowledge.
`
`Executed on October 29, 2015
`
`Alan F. Siegrist, CT
`CROSSLINGUAL, LLC
`ATA Member No. 31889
`Certification #63788
`
`A notary public or other officer completing this certificate verifies only the identity of the individual who signed the
`documents to which this certificate are attached, and not the truthfulness, accuracy, or validity of that document.
`
`.5
`
`State of California, County of G(\‘lT7l
`Eat) Jer-
`Ggc/&luxo5,
`On aolfi
`before me,
`who proved to me on the basis of satisfactory
`.
`personally appeared Cl l
`/l
`a.
`evidence to be the person whose name us subscribed to the within instrument and acknowledged to me
`that he executed the same in his authorized capacity, and that by his signature on the instrument the
`
`person, or the entity upon behalf of which the person acted, executed the instrument.
`
`I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
`paragraph is true and correct.
`
`Witness my hand and official seal.
`
`..
`
`fl
`
`, mmuum mun “Wm
`«
`COMM. 0
`
`~
`
`Signature
`
`Page 1 of 5
`
`SENJU EXHIBIT 2111
`
`LUPIN v. SENJU
`IPR20l5-01100
`
`
`
`May 2000 — Crmted (New Format, First Edition)
`
`Storage Method: Room temperature storage
`Expirmimiz
`Tobeusedbyflieezqnmtiondatedisplayedonflieextuiorpackage
`(even before expiration, tobeusedprmnptlyafieropening).
`
`Japan Standard Commodity Classification No. 871319
`2l200AMZ00l68
`
`1997
`
`July 2000
`J
`
`Non-steroidal anti-inflammatory ophthalmic agent
`
`Designated Prescription Drug BRONUCK° OPHTHALMIC SOLUTION
`Bromfenac sodium h
`te o hthalmic solution
`
`The following adverse effects were observed in the foregoing
`o
`
`S
`
`0.1% to less than 5%
`Blepharitis, oonjrmctival hyperemia, stinging, ocular pain
`(temporary), corneal inflammation, corneal epithelial abrasion,
`
`. K
`
`3. Administration to Pregnant, Parturient, and Nursing
`Women
`
`Administration is to be conducted to pregnant woman or
`women who may have conceived and to women who are
`nursing only when it is judged that the benefits of treatment
`outweigh the risks.
`(The safety of administration during pregnancy and lactation
`has not been established.)
`4. Administration to Children
`
`Safety relative to children has not been established (there is
`little experience with use).
`5. Cautions for Use
`
`(1) Administration route: only to be used for ocular instillation
`(2) At time of administration:
`ocular instillation. take
`care so that the lip of the container does not directly contact
`the eye.
`[Pharmacolrinetics]
`(Reference)
`Intraocular Migration <rabbits>1)
`In testing wherein ocular instillation of 0.05 mL of 0.1% “C-
`bromfenac sodium hydrate ophthalmic solution was conducted
`once a day is both eyes of rabbits. and radioactivity was
`measured after 15 minutes. 30 minutes. and l. 2. 4. 8. 32. 24.
`48. and 72 hours. elevated values were observed in the cornea.
`conjunctiva. and anterior sclera.
`At 72 hours after ocular instillation. all ocular tissue except
`for the lens was below the detection limit (0.1 ng eq.:’g or
`.r§&: ‘gr-ml?
`Conn
`
`_ :“'“_m' a
`"Anterior" vrtreo'ushnmor
`' Blood
`
`
`
`
`
`
`
`Bmmfenacsodiumhydateconcentration
`
`
`
`
`
`
`
`[Contraindications (do not administer to the following
`patients)]
`Patients with a previous history ofhypersensitivity to the
`'
`- dients ofthis dru
`
`Ingredients] content
`(in 1 ml)
`
`Additives
`
`.
`Bromfenac sodium hydrate 1 mg
`Bmic acid,borax,drysodinmsulfite, sodium
`edetate, povidonc, polysorbate 80,
`bennlkonium chloride
`
`‘_
`
`m [
`
`_
`_
`Eflicacy / Effects]
`Symptomatic treatment of inflammatory ailments of the
`external eye and anterior eye (blepharitis. conjunctivitis.
`scleritis
`(including
`episcleritis).
`and
`postoperative
`inflammation)
`[Usage / Dosage]
`Ordinarily.
`l-2 drops per administration. and 2 ocular
`instillations per day.
`[Cautions for Use]
`1. Important Basie Cautions
`(1) Keeping in mind that treatment by this drug is symptomatic
`treatment
`rather
`than causal
`treatment. and that
`it
`is
`reported that serious liver damage (including death) has
`been observed
`in patients
`subjected
`to
`long-term
`administration of 1 month or more with the oral agent of
`bromfenac sodium. continuous administration for 4 weeks
`or more is not conducted in principle. Although the
`aforementioned adverse eflects observed with the foreign
`oral agent were due to long-term administration exceeding
`the approved usage and dosage. sales have been vollmtarily
`suspended.
`(2) As there is risk that eye infection may become subclinical.
`in case of use on inflammation resulting from infection.
`administration is to be conducted carefully with adequate
`observation.
`2. Adverse Efleets
`
`At the time of approval. adverse eflects had been observed in
`16 out of a total of423 cases (3.78%).
`With respect to the content of adverse effects. there were
`3 cases of blepharitis
`(0.71%).
`3
`cases of conjunctival
`hyperemia (0.71%). 3 cases of stinging (0.71%). 3 cases of
`ocular pain
`(temporary)
`(0.71%).
`2 cases of
`corneal
`inflammation (0.47%).
`1 case of conical epithelial abrasion
`(0.24%). 1 case of superficial punctate keratitis (0.24%). 1 case
`of follicular conjunctivitis (0.24%). 1 case of pruritus (0.24%).
`and 1 case of burning sensation (eyelids) (0.24%) (at the time of
`approval).
`
`Page 2 of 5
`
`
`
`[Principal Literature]
`1) Mitsuyoshi Isaka et al.: Pharmacokinetics, 14 (1) 32, 1999
`2) Takahiro Ogawa et al.: Journal of Japan Ophthalmology Society, 99, 406, 1995
`[Contact for Requesting Literature]
`Scientific Information Department
`Senju Pharmaceutical Co., Ltd.
`5-8, Hirano-machi 2-chome, Chuo-ku, Osaka-shi, Osaka
`
`Marketed by: Takeda Pharmaceutical Co., Ltd.
`
`1-1, Dosho-machi 4-chome,
`
`Chuo-ku, Osaka
`
`Package 00-009
`
`
`
`
`
`
`
`
`
`Efficacy rate (%) and
`effectiveness
`66.7 (6/9)
`63.2 (60/95)
`63.6 (7/11)
`86.4 (152/176)
`77.3 (225/291)
`
`relative
`
`to
`
`experimental
`
`[Clinical Results]
`A summary of results with respect to 291 cases including
`double-blind comparative testing are shown in the table.
`For the most part, daily dosage and administration period
`were 1 drop per administration and 2 administrations per day
`over a 2-week period.
`Table. Clinical Effects by Ailment
`Name of ailment
`Blepharitis
`Conjunctivitis
`Scleritis (including episcleritis)
`Postoperative inflammation
`Total
`[Pharmacoefficacy and Pharmacology]
`1. Pharmacological Action
`(1) Anti-inflammatory
`action
`conjunctival chemosis in rats2)
`It was observed that Bronuck ophthalmic solution exhibited
`anti-inflammatory action relative to experimental acute
`conjunctival chemosis in rats induced by arachidonic acid
`and carageenin.
`(2) Inhibitory effects relative to increases in aqueous humor
`protein concentration in rabbits after anterior chamber
`paracentesis or after laser irradiation2)
`It was observed that Bronuck ophthalmic solution almost
`completely inhibited increases in aqueous humor protein
`concentration in rabbits after anterior chamber paracentesis
`or after laser irradiation.
`2. Mechanism of Action
`In tests using rabbit iris-ciliary bodies2) and bovine seminal
`vesicles, it was confirmed that inhibitory action was exhibited
`against production of prostaglandin inflammatory mediators via
`cyclooxygenase (in vitro).
`[Physicochemical Findings Relative to Active Ingredients]
`Generic name:
`Bromfenac Sodium Hydrate (JAN)
`Chemical name:
`sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate sesquihydrate
`Molecular formula: C15H11BrNNaO3 · 1½ H2O
`Molecular weight: 383.17
`Structural formula:
`
`
`Properties:
`
`
`
`
`Bromfenac Sodium Hydrate is an odorless
`crystalline powder of yellow-orange color.
`It is freely soluble in water, soluble in
`methanol, slightly soluble in ethanol
`anhydride, and practically insoluble in
`acetonitrile or ether.
`
`[Packaging]
`5 mL × 10, 5 mL × 50
`
`
`
` Manufactured by: Senju Pharmaceutical Co., Ltd.
`
`
`5-8, Hirano-machi 2-chome,
`
`
`Chuo-ku, Osaka
`
`Page 3 of 5
`
`
`
`200044-15 Hmaz<mMas1r.a)
`
`-4=’ZiH9H!3
`iii :
`1!?
`fifllllfilfli I 5'1-NH:J€Il30)11EJiJlUJfliP~JI:H1fll’§‘Z> .2 t(1'l1JfUUll9il’i'C'
`&;«;'C i» .
`|3|J.l’-H&l152E‘<’7)\£:f'L‘fll'¢‘Za C. t)..
`
`n4<4:»m.:.'.mrm
`IR
`fr‘
`'0'’
`2l200AMZ00l68
`as in nu az
`2000‘!-15)!
`IE EB
`#15
`zooofifi 7 B
`M as m It
`49974-2 7 n
`
`3527‘ El 4 F‘l§}i"1.fi11T_J.‘—.TflE§'J
`
`W'**‘* 7"D7"'J97;'=.'.flE§f§
`
`BROMJCK’OPHTHALM|C SOLUTION
`‘J‘l3L\7I1'77' l'~'J'7A 7J<¥£M rrfiflfifii
`
`L1T<7)flH’Efflli I2?-EV).’sW‘§:'C‘§i4!.a?) Fpflf: 1; 0'63; 60
`
`mm. ifififtllll. ililliiffi. BRfi[*i§11Ii].
`filfififl. fiilfiilzriiflk.
`.-.'.(4}t2i7§f8R
`fifiiflflfl. fiifilé. §!M:‘!e[llflW]
`
`7’r1A7x')‘7+l~'J"Jl. dcflliblmg
`
`i£)5é£JiLf;5£%t:4;t.
`
`!’:t—':¥’$:*l1Jl;‘W5:. to
`
`3.tIfi. Efi. 1§3Lnw«oms
`&Efi1litT:fiL'Cu~biIfiE‘l't0)2;Z»El\&E)‘§§¥1.'1‘0)
`fiAz:4:tié4fi.I;a>1m1M*mfift& J:Ifi.l6!:-’F]|fi‘é11.
`z>J%’c.*t:o).7+¥i'H'6:to
`[lfl':bE'1‘)StU‘¥§'+’LrtW>¥9:i:‘-I:f!El*J'Z.a'££%1?EliR£fiLfw
`7§3'I‘o]
`
`4.IJ\bE$'\0m—5
`IJ~bH¥H:ir-H"z>ié:em:€£:LL~tw:cu~(491mm»W
`mm).
`
`5.i!=HJ-_a>~;:t
`(1)?§!15&2£:.=.‘:2llRfF!t:a)J;.f§1ffI'3‘J5:. 2:.
`(2)!!! 15 as : .«.:.<w>a as. %§%30>9e9w><1E::1&I3z:n!zn
`7Scl.\J: fiazitfitaz to
`
`KIMIMH
`(3 6')
`lmfl-‘r(r7+M—’>"
`.r.'.-‘Mil
`-7+r=Fo7)|fiifliI:0.1%"C-7nA7:1-7-r l~') 71. 4:41:44;
`0.o5mL&1Ir-I.-.?.I1HL. 15. 309}. 1. 2. 4. 8. 12. 24. 48. 72115
`lfllffilllifllli-lii*:t'E§'il¥l23£Lf.:.‘.v\2R‘(‘l1. #15:. $*.76U§.0‘uiiI.‘iS5‘£llHI:
`4!‘-‘ifnliiir/|'iLf.:a
`/It-E'u4Jk*S:l%<1*«<'ca>I1uiIlI?&T-mlxlfiiw
`.-.‘.(Im£z72II3*l-'ll'(-4:.
`(0.lng eq./g or ml.) 11 l"’C'5) *2 to
`(n: «J: av n1)
`
`--
`
`z A I
`:33 l
`I I33!!!
`I ITIHIK
`in]!
`SI!
`\\\\\\\\\ : mmmnu?
`n=3
`
`10‘
`
`8
`
`
`
`K533i’L‘\h:*r‘+\)V|-H\JI>D\l
`
`:h-74912. mamr-.sem+m«;z.. 1
`rt-7412.
`?’|~&'}‘}~')"I1».
`.1:ur'>. =K'J'/Iw\'—
`|~go, }fifl;z<‘/-ii-’)I«:1;-VA
`
`/k1'E.x'.I‘.l|lUFl
`
`(R1132 - 331$]
`91-IRn‘fl5£iU‘i‘a?iBIvlflV)flé1:E1‘!t¥5é.@.0);’t-Ifirifiiili(llfififi. filfi
`ifil|E$2(.l;$1iR$é’&’r3‘!‘:).
`
`{R352}-FE!)
`SE13‘. 1rciI1~2ifi. 1lI2l.fi,I.I.‘iflE'd‘Z»o
`
`l{!F§J:0)3Ifil
`1. iatstaaiit
`m4:a‘m:.,t bihifllifiilflifiiffcit < ;r~Hrr.J££i1;-f-aims
`:tKfifiL.it.%WK£wT.7uA7;+
`7+ l~')")1..¢)$1-lZli'i1J’i'1¢: HL1_l;Ewi¥i£iLr_-.@.
`H-c:.ifi&IlfFfi%(éfité-’;%t:)7)*32d>v;nr;to>fl
`'.-*.-v)‘zM»o>r-. usianz: L1 4 5§flfiL11:0)fl#.§‘é-Y£—”:-ti
`fi7b7§:\.\..‘.to >:c:—.s. 9+l:|a)#£LIfiJn:3£ab»3n7;J;
`3r:<nal4’£m4:23<32.o>ItJi£ - ififi§'&2.f:fi1Ui¥i4‘-H:
`;6$®f$5#.fl¥muMfi&WmLfwLo
`(23liR0)!é.§!{!¥fi=1%2K<¥£‘i‘P'¥.{l:'§‘Z>:fo‘{‘fL7!J‘af~;Z>0)'E. ewe
`u;6fi&uflLrmm6%euufi§%+»ufi
`1».
`tM;4:&‘—i1"z. .: to
`2.014139
`7Ké2H#'ea>;s€i:E{9IJ423f9!rtr164?l
`'5“-ffio
`WJ1’Fffil’~J¥f-G1. I1m32314=(o.71%). «k%‘m9‘f.mL3f«‘r(0.71
`96). sifllmfiafi-(0.71%). naaa:s£44;a44:134rr-<o.71e<.>. ff:
`7£IfiiiI24'H0.47%). iraaumnx 1 fr-(0.24%).
`E¢m32144(o24%>. 4maana144:<o249<.>. Jfiiiafi 1
`{'4 (0.24%).
`;!M&[nm] 1 f4‘(0.24%)'C‘§)of.: (34244).
`
`(3.78%) c:aiIJf’r:flI7)=.%.".ab
`
`Page 4 of 5
`
`
`
`
`T
`i
`_
`[fiu‘=?.r'2Efi£!I%]
`
`
`:mE&mfifiMa%&fitammuomrwmfiflfiufiwt
`
`
`
`
`3Uv&&o”— T
`T
`
`
`
`1H#’;zf.+fi\ J’£’4’»JU]JiiJIidt’.%{$5}7b*1[Elffi\ 1El2lEl. 255
`
`
`
`
`
`
`
`
`
`
`
`I.'urv2'Iaz,.a
`'
`‘A
`
`
`
`
`
`;;§,g;x§;u|33,;n:§J;J,g.
`
`
`
`
`
`
`
`llfi 32
`iii
`
`
`
`(J:fi1i":E5é’«?."%tr)
`
`é
`
`
`KEESZEU
`D#W%fim:¥%mEJMD31m%.
`
`
`
`
`
`
`m¢Wfifim:H$MH%%%%3awaw%-
`
`
`
`
`
`
`
`A
`M
`~
`V T
`\
`[S£fifi§§Sfi5‘E]
`
`'5
`
`M
`
`
`'
`
`
`J?§fa%fl£%55ti$’4éi’Cé’:'¥t
`ififfiffffififils
`
`
`
`
`
`
`
`?Mrmw~xfimwmE$MM4TH5fi8%
`
`'
`
`T
`fifi$@@fifimi.
`
`
`
`
`
`55.71 "ex '9)
`
`
`63.2 ( 60/ 95)
`
`
`
`
`
`
`%£(7/u)
`
`
`
`
`
`86.4 (152/176)
`
`
`77.3(225/291)
`
`
`
`.
`
`
`
`
`
`
`
`
`
`-@fifi&3&fiE.
`
`if
`
`
`é?
`
`
`
`
`lfifififll
`
`_-
`-
`_A
`L¥E¢fi
`
`(1)72 I~¥fiEI’»IfiE-}¥H§I:i~fi”5fi3é§E1’fififl“
`
`
`
`
`7Ufv%fiMflfi9vFtfiWé75#F7$\fififz
`
`
`7 I: i 2;» 3'él§'}‘<Fl‘J%'.'f£$i%‘JIi‘§i1§‘-J§fil:.'.i'~J‘ L¥;'1;%5'fi1’:”=Hi i'i<’§'C a 75‘
`
`
`
`
`
`
`§.’J.ab£»:i’Lf:n6o
`‘
`‘
`'
`
`
`(2)'7+2‘¥'n‘fiE$fii|l?£1£;t Lz—'b"—fii=i§=lf§0)E7J<§EI>EI'=%€i§TJnI:
`
`
`
`
`
`
`
`
`
`-
`fiiaflflfifi“
`
`
`
`
`
`
`7p%v¢fimfim¢#¥usuamE$W%I¢u—W—
`11%?-5ii}1"i20)E7l<EIEI:'&f%‘El¥‘3iilI E lit1=f.3%&C§Hiff'|J1‘»T:~, : .1; 75*.‘%£ab
`
`
`
`
`
`
`anruwzm,
`
`
`2. flsmfififiv‘
`
`
`
`flfi¥fl%%fi¢“&U¢vfifiémmtfifikfiwf;97
`
`
`
`
`
`
`
`n#$9V+~€&fiTé7ux9V5vvy%mfifix?4
`
`.-n—- 57 -£Iar:JaJ1IIfl2+J1’EIE éfrwfc a 2h<Fté%.E=§ 11n'»z»(in vim»);
`
`
`
`
`
`
`
`
`
`
`
`
`[EfiW&NU?6EfififlflfiJ
`~&%:7uA71+a++u¢Amm%
`
`
`
`
`
`
`
`
`(Bromfenac Sodium Hydrate)
`[JAN]
`
`
`
`
`‘I|$‘—‘:u"‘5E I sodium 2-amino-3-(4-bromobenzoyl)phenylacetate
`
`
`
`sesquihydrate
`
`
`: C15H11Bl‘NNa0:s‘ 1%H20
`5}—T—;-at
`
`
`
`
`i}%‘fi1: 383.17
`
`
`Wifiit 2
`
`
`H
`
`7
`
`‘
`
`
`
`\
`
`
`
`El)
`~
`B1-— —C
`
`H,N
`
`
`
`CH,C0,Na-11/2H,O '
`
`
`
`
`
`:7’uL7.:-I-7-J'}~ 'J"J1=. 7I<$l11‘|2Irl.;t.‘iI':‘f£'.'-fiiav-‘fig-:?)fisEE:
`
`
`
`
`’r$m5}3|a’Cx l:3;—.w~:i>5-too
`
`
`$KfiH@¢<.x9/~»u@¢fifi$f<.fiml
`
`
`a/—wufiwu<<.7tL;ru»xm1—¢»u
`
`
`a:am;w':~:-n2:.-u~0
`'
`
`
`
`
`
`
`
`
`
`ta
`:1
`5mLx10‘5mLx50”
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`flE$flI¥fifi%fi*
`i:B!iifiEP9éI3_<‘.m§I|lIIElT E Hfrl-E‘
`
`
`
`
`
`
`Page 5 of 5